Le a le KRAS G12D Deal ma Biotech Supply Chains Moni A'afia ai
luga 2026-09-28, Na ulufale Merck i se maliliega fa'alelalolagi laisene fa'atasi ma le SciBrunch Therapeutics mo le SPR2015, se KRAS G12D tu'u gutu su'esu'e (IA) inhibitor. Merck totogi $400 miliona fa'asaga i se tau aofa'i fa'atatau o $2.13 piliona, ma ave aia tatau i le lalolagi atoa e atiina ae ai, gaosia ma fa'atau pisinisi le fa'afefiloi (Merck & Co. fa'asalalauga fale talafou, 2026-09-28). O le aseta e fa'apitoa: o se kelu mole faʻatasi ma le nanomolar antiproliferative gaoioiga i laina sela mutant, e le'i tofotofoina i tagata.
E lua faʻamatalaga faʻapipiʻi le fefaʻatauaiga. Tulaga tasi, o le laisene e la'ititi ma fa'atotonu: SciBrunch o loʻo faʻauluulu i Shanghai ma na faʻavae i le tuai 2024 (Merck & Co. fa'asalalauga fale talafou, 2026-09-28). Tulaga lua, Merck o le a tusi a $400 miliona totogi a'o le'i totogiina lafoga, e uiga i $0.13 i le sea, i lona q3 2026 i'uga (RTTNews, 2026-09-28).
O le $1.73 piliona le eseesega i le va o le $400 miliona i luma ma le $2.13 piliona ulutala o le nofoaga autu taua, e le o se fa'asologa o totogi fa'asalalau. E pei o one specialist trade analysis of the terms points out, 18.8% of the advertised total is committed money, and the milestone split, royalty rate and territorial carve-outs were not disclosed (Small Molecule News, 2026-09-29).
The founder’s prior out-licensing track record is part of the deal’s context: chairman and CEO Tao Hu previously led the global exclusive licensing of preclinical oncology program UA022 to AstraZeneca in 2023, and he and co-founder Yang Zhang came from WuXi AppTec, with Hu having earlier worked at Merck and Amgen in the US (Small Molecule News, 2026-09-29).
Aisea e Taua ai Lenei Fefa'ataua'iga mo Biotech Supply Chains
lena $400 million upfront is best read as a statement about competition, not about the asset’s maturity. Revolution Medicines’ zoldonrasib (RMC-9805) is already in Phase 1/1b in KRAS G12D-mutant solid tumors with 2026 data and a Phase 3 first-line pancreatic trial, ma na maua le FDA Breakthrough Therapy igoa ia Ianuari 2026 (Vailaau Fouvalega, 2026-01-08). O le totogiina o lena tau mo le ulufale muamua e atagia ai le tauvaga mo sui tauva RAS-alaala eseese (Tekonolosi Fa'atekonolosi, 2026-09-28).
O lena fausaga e gaoioi kemisi, gaosiga ma pulega galue muamua. Talu ai na maua e Merck aia tatau o gaosiga i le tulaga muamua, auala gaosia, au'ili'ili metotia ma fa'amatalaga o le a mana'omia le fa'ase'esega a'o le'i faia muamua su'esu'ega a le tagata, ma stereochemistry, fa'ailoga le mama ma le fa'atonuga fa'atututonu i le fa'atusatusaina (Tekonolosi Fa'atekonolosi, 2026-09-28). O le mea e fai ai lena galuega e le faaituau: o le au'ili'iliga lava lea e tasi o lo'o fa'aopoopoina e le FDA ni alagaoa mo asiasiga mai fafo, e aofia ai nisi Vaega 1 ma fa'ata'ita'iga muamua (Tekonolosi Fa'atekonolosi, 2026-09-28). O fa'amaumauga fa'atekonolosi fa'atekonolosi e avea ma fa'alavelave ola i le tulaga o le fesiitaiga, e le o le faila.
O le voluma i tua atu o fefaʻatauaiga faʻapenei e tele ma faʻatupulaʻia. O lipoti a le Vision Life Sciences $136 piliona e tusa ma 157 fa'ailoa mai e Saina le fa'atagaina o fefa'atauaiga i totonu 2025, faasaga i $51.9 piliona i le lautele 94 fefa'ataua'iga i totonu 2024, fa'atasi $60 piliona ile Q1 2026 toatasi (Vision Life Sciences, lomia faasalalau 2026-06-27). Fai na mea o ni laina: e ese le faauigaina e le au tala'i tau tau, ma o fuainumera o lo'o fa'aalia le aofa'i nai lo tupe su'etusi.
E to'atolu pa'aga na latou faitauina lenei mea. E maua e le aufaipisinisi tetele se tagi muamua i se sui tauva ese ae vave ona latou mauaina le avega o le fesiitaiga. O le laiseneina o meaola fa'aola mai Saina e maua ai tupe i luma ma leiloa sa'o le fa'atonutonuina o le auala ma le fa'aputuga o metotia. O pa'aga tu'ufa'atasia ma au'ili'ili o lo'o tautua uma e fa'amalieina le galuega: atinae auala, fa'atulagaina fa'amatalaga ma fa'amaumauga o lo'o nofo nei a'o le'i su'esu'e muamua-i-tagata nai lo le mae'a.
O le a le mea e manaʻomia e le Synthesis and Analytical Partners
A molecular glue stabilizes a ternary complex rather than occupying the KRAS pocket (Thoracic Cancer review of KRAS G12D inhibitor design, Tesema 2025), so stereochemistry, impurity profile and solid form become comparability levers that must hold across sites and scales.
What travels in a transfer package is the method, the reference materials, the specification and the raw data. What often does not travel is the tacit knowledge behind them, which is why the receiving lab has to re-satisfy I Q2(R2) Validation of Analytical Procedures (final, Mati 2024). Analytical method transfer is quoted by CDMOs at $150,000 ia $400,000 per package, with repeat qualification at $20,000 ia $100,000 per method (Drug Patent Watch CDMO price benchmarking, Mati 2026). Fai i latou e pei o fa'atau-fa'atautala fa'atatau i fa'atauga maualuga fa'aituau, e le o tau maketi.
“Mama maualuga” i se faila e faauigaina e I Q3A(R2) Oona i Vailaau Fou, lea o lo'o nofo ai faitoto'a i le PDF nai lo le itulau e tula'i mai. O se tusi faamaonia o au'ili'iliga o lo'o lipotia mai ai se numera tasi e aunoa ma le fa'ailoga le mama i tua atu o lo'o ta'u mai ai pe fa'aola lena fa'amatalaga i luga ole fa'atuputeleina. I fa'asologa faigata, GenScript lipoti 93.81% manuia i ana NeoPre dataset (1,030 tuuina atu o 1,098 taumafai) i luga o lona itulau fa'atekinisi. O le fuaina lea a le tasi tagata fa'atau oloa i lana lava fa'amatalaga o le "faigata,” e le o se fua faatatau o pisinisi.
Se faʻamatalaga i luga o a matou faʻamaoniga: leai se fa'ailoga isi vaega, leai ni fa'amatalaga fa'atino a le vaega muamua e mafai ona su'eina ma leai se fa'atauga su'esu'ega na maua mo lenei su'esu'ega. O le mea o lo'o mulimuli mai o se fa'avae o ta'iala e fa'aoga, e le'i fa'amaonia i'uga.
Tulaga
O le a le mea e fesili ai
Oka se tali vaivai e foliga mai
Taimi ta'amilosaga
O suiga masani mo se vaega SAR 40-analog, ma o le a le mea e mafua ai feeseeseaiga?
Ole numera pito sili ona lelei e leai se eseesega
Sa'o-taimi muamua mama
Faʻasaga i le faʻamatalaga, fuaina pe faapefea, pe fia vaega?
“>95% mama" e aunoa ma se faʻamatalaga poʻo le aofaʻi o vaega
Fa'atusatusaga fa'aleaga-fa'atusa
Automated Peptide Synthesizer E faʻafefea ona faʻaalia le faʻamatalaga mai le mg i le kg?
O se faʻamatalaga e faʻapea o faʻamatalaga "tumau tumau" e leai ni faʻamatalaga
Pulea fa'ama'i
Nofoaga Suesuega Neuroscience O fea nofoaga tutotonu e taua tele, Biosynthesis o le Hormone Peptide ma pe faapefea ona pulea taitasi?
Diastereomer ratio sii mai e aunoa ma se metotia poʻo se faʻatapulaʻaina
Metotia-atinae gafatia
Is method development run alongside synthesis or after it?
Analytical work quoted as a separate, later phase
Documentation and chain of custody
Can you show timestamps, handlers Bones And Joints Research and transfer purpose per lot?
A COA with no underlying raw data trail Cancer Apoptosis Research
IP handling
How are trade secrets ring-fenced across sites and borders?
Reliance on an NDA alone, with no operational controls Peptide Hormone Synthesis
Two rows carry more weight for a cross-border program. Chain-of-custody and data-integrity records, plus the licensing documents establishing title and scope, are what make a package portable between a China-origin licensor and a US licensee; China-side formalities can include technology export contract registration and, for covered data, CAC mechanisms (J. Chang Law i le laiseneina tekinolosi mai Saina, Ianuari 2026). O le taʻitaʻiga a le fomaʻi, e le'i fa'amautu tusitusiga fa'atonutonu. O le auala pepa GMP e mulimuli i le API o loʻo pulea eseese i lalo ICH Q7 Fa'ata'ita'iga Fa'ata'ita'i Fa'atino Gaosiga Lelei mo Mea Fa'ato'aga Fa'agaioiga (final, Setema 2016), ma o le tala o le atinaʻe e tatau ona taʻu mai e le auala o loʻo tuʻuina atu i totonu ICH Q11 Atina'e ma le Gausia o Vailaau Fa'asaina (final, Novema 2012), fa'afanua ile CTD Module 3 vaega 3.2.S.2.2 e oo atu i le 3.2.S.2.6.
E tasi le mamanu e tatau ona tofotofoina i se talanoaga: pe fa'atautaia e se paaga le atina'eina o metotia fa'atasi ma le tu'ufa'atasi nai lo le mae'a. MOL Suiga o se tasi o faʻataʻitaʻiga o se paaga faʻatulagaina i lena auala. Fai i sui tauva uma le fesili lava e tasi ma faatusatusa sa'o tali.
O le ta'amilosaga fa'ata'amiloga mole mole pu'upu'u e seasea maua mai na'o le kemisi vave. E sau mai galuega su'esu'e o lo'o fa'agasolo tutusa, se afifi fesiitaiga ua fa'apotopoto a'o le'i filifilia se sui tauva, ma fa'amaumauga fa'atekonolosi fa'alava i tua'oi e mafai ona fa'atino e le fale su'esu'e e aunoa ma se telefoni.
Le Ata Tele ma le Mea e Fai Nei
O le fefaʻatauaʻiga a Merck e fetaui ma se mamanu na muamua atu: tulaga fa'apitoa, Laisene i tua atu lea e vave gaoioi ai aia tatau, a'o le'i maua e se sui tauva se su'esu'ega ile falema'i. O le uluai faʻavae o le faʻavae oncology laiseneina ma AstraZeneca na mulimuli i lena foliga i totonu 2023, ma le 2026 fa'ata'ita'iga KRAS G12D o lo'o nofo i le isi pito o le arc lava e tasi. E lua i'uga e mulimuli mai mo so'o se tasi e maua le malosi fa'aopoopo. O le saunia o le fesiitaiga ua avea ma mea e fa'ailo ai nai lo le fa'atonu, ma o le su'esu'ega o lo'o fa'atusalia ai le filifilia o nofoaga ua aofia ai le fa'aalia o asiasiga mai fafo, ile ta'iala a le FDA ile faiga ole asiasiga i fafo.
Fa laa, faatonuina i le faanatinati:
-
Su'e lau paketi fesiitaiga a'o le'i filifilia se sui tauva. Afai e le'i fa'aputuina le seti fa'amaumauga i lena taimi, e avea ma ala taua.
-
Fa'aagavaaina vave le su'ega malosi. O lipoti a le Foma'i i le Drug Discovery News e tu'u ai le agava'a su'ega i 6 ia 12 masina, lea e umi atu nai lo le tele o polokalame e fuafuaina.
-
Fa'amaonia tuutuuga o le pule-o-le-puipuia ma au'ili'ili-fa'amaumauga a'o le'i sopoia le tuaoi o laisene. O nei mea e sili atu ona faigata ona toe faʻatalanoa mulimuli ane.
-
Tala fa'atatau o le tu'uina atu, aua le mitiia. Fa'atau le tau ma le taimi o le fesiitaiga o se mea laina, e le o se faalavelave faafuasei.
Aua:
Fa'apea o se pasene mama mama e suitulaga mo le fa'atusatusaina o fa'amatalaga le mama i le fua.
Tolo'i le fesiitaiga o metotia se'i mae'a le filifilia o sui tauva.
Afai o lo'o e iloiloina paaga mo se polokalame fa'apenei, talanoa i se tagata poto faapitoa e uiga i mea e mana'omia e lau afifi fesiitaiga.
Fa'aaliga: O Suiga MOL e iai sona fiafiaga faapisinisi i tulaga lelei o le peptide.
Fesili e Fai soo
O le a le mea na fa'atau moni e Merck, ma o le a le tulaga?
Na maua e Merck aia tatau i le lalolagi atoa e atiina ae ai, gaosia ma fa'atau pisinisi SPR2015, se KRAS G12D tu'u gutu su'esu'e (IA) inhibitor (Merck & Co. fa'asalalauga fale talafou, 28 Setema 2026). Na maua e SciBrunch Therapeutics se $400 miliona totogi muamua, ma le aofa'i o le tau aofa'i o le fefa'atauaiga, e aofia ai lena i luma, aapa atu $2.13 piliona. Ua tapunia le feagaiga.
Ua fa'ata'ita'iina le SPR2015 i tagata?
Leai. O loʻo faʻamatalaina e Merck le SPR2015 o se kelu molecular molecular suʻesuʻe malosi ma filifili faʻatasi ma le nanomolar antiproliferative gaoioiga i KRAS G12D-mutant cell lines (Merck & Co. fa'asalalauga fale talafou, 28 Setema 2026). O mea uma o lo'o i lalo e fa'atatau i le su'esu'eina ma le fa'atinoina o sapalai, ae le o fautuaga faafomai.
O a suiga mo se synthesis po'o se paaga su'esu'e o lo'o tautuaina se polokalame fa'apenei?
Fa'afeiloa'i sauni gaioi muamua, ma avea agavaa su'esu'e malosi ma pou umi. O se paaga e le mafai ona agavaa se su'ega a'o le'i mana'omia e le sponsor e fa'agesegese le tu'uina atu atoa.
Pe suia e le fefaʻatauaʻiga manaʻoga mo le faʻaogaina o le peptide?
O le tasi maketi-suʻesuʻega faʻatusatusaga tuʻuina le peptide synthesis ile USD 732.58M i 2026, aulia le USD 1,438.78M e 2035 (Fa'amuamua Su'esu'ega, 2026), a o se fua faatatau lona lua, i se tulaga ese, e maua ai le USD 0.98B i 2026 siitia i le USD 1.54B e 2031 (MaketiMaketi, 2026). O fa'amatalaga lautele a le lomitusi e 'ese'ese i le 3x, o lea ia aua ne'i avea se ata e tasi e tauave-avega.
Fa'ai'uga
Merck's $400 miliona KRAS G12D fefa'ataua'iga e sili ona faitau e fai ma fa'amatalaga e uiga i le fa'atatauina o aseta muamua, e le o se faaiuga i le vaega. O taunuuga fa'atino e vaapiapi ma sili atu ona fa'atino: o le saunia o le fesiitaiga ua avea nei ma mea e fa'atosina ai i le fa'ata'ita'iina o laisene, ma paaga e le mafai ona fa'aalia vave fa'agesegese se polokalame i le taimi tonu e sili ona taua le saoasaoa.
O lena e suia ai tulaga o iloiloga e tatau ona e talosaga. Taimi ta'amilosaga, mama sa'o-muamua fa'asaga i se fa'amatalaga ta'ua, fa'atusatusaga fa'atusa i luga ole fua, auala-atina'e gafatia, fa'amaumauga ma le fa'afoeina o le IP o fesili ia e tatau ona fai a'o le'i sainia se polokalame, e le'i uma. E fa'amasinoina se paaga peptide synthesis fetuutuunai i na itu e ono, ma pe fia le tele o faʻamaoniga ua uma ona i lima nai lo le folafolaina.
O le fesili o lo'o va'ava'ai i luma pe o le fa'aliliuina o aia tatau a'o le'i fa'ata'ita'i-laasaga o le gaosiga e avea ma fa'aletonu nai lo le fa'ate'a. Afai e fai, o paaga na saunia i ai o le a avea muamua ma polokalame e ausia.
Talanoa i se tagata tomai fa'apitoa po'o talosaga se su'esu'ega fa'atino e va'ai pe fa'afefea ona fa'asagatau le sauni atu o lau polokalame i nei ta'iala.
